When Do You Start to Feel Wegovy Working?

The decision you're really making: patience or progress?

When Wegovy arrives (in plain, unbranded packaging with a DPD tracking update on your phone) it is tempting to expect an immediate shift. That is the question most people are quietly asking: is this actually doing anything yet?

The honest answer is that Wegovy works in stages, and the early stage is about biology, not the scales. Semaglutide activates GLP-1 receptors involved in appetite regulation and slows the rate at which the stomach empties. Those changes begin with the first injection, but they build gradually as both the hormone level in your body rises and your prescriber titrates the dose upward over weeks. Understanding which signals belong to which stage stops you from drawing the wrong conclusions too soon.

There are three broad phases most people move through: the early adjustment phase (weeks one to four), the dose-building phase (roughly weeks four to sixteen depending on how titration goes), and the maintenance phase where the most significant changes in body weight occur. The Wegovy overview covers the full licensed dosing pathway in more detail.

Each phase has its own signals, and reading them correctly is what this page is about.

Weeks one to four: what 'feeling it' actually looks like at the start

The first signal most people describe is not dramatic. It is a reduced urgency around food, meals feel sufficient without the usual push to finish the plate, or afternoon snacking just loses its pull. This is appetite suppression beginning to work, and it can appear within the first few days of the starter dose for some people, or by the end of the first two weeks for others.

What most people do not feel in week one is significant weight loss. The starting dose is set low deliberately; its job is to let your system adjust to the medicine rather than to produce the full therapeutic effect straight away. Weight on the scales may barely move at this stage, and that is completely normal.

What you may feel instead, alongside the quieter appetite, is some gastrointestinal discomfort: nausea, burping, loose stools, or a sense of fullness that tips into queasiness. These side effects are the most common early response and are generally mild to moderate; for most people they settle within days to two weeks as the body adjusts. Eating smaller portions, staying well hydrated, and avoiding rich or fatty meals at this stage makes a practical difference. If symptoms feel severe or persistent, contact your prescriber.

The NHS semaglutide patient information page has detailed guidance on managing early side effects, see the NHS semaglutide guidance for the full list of what to watch for and when to seek medical help.

Weeks four to sixteen: when the weight actually starts to shift

As the dose increases through the titration schedule (0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, each step typically held for about four weeks) the effect on appetite deepens. This is when most people start to see consistent, measurable weight loss each week.

The rate varies. Some people lose steadily from the first dose increase; others find the most noticeable shift happens once they reach 1.7 mg or the 2.4 mg maintenance dose. That variation is normal and does not mean the medicine is not working. Factors including starting weight, diet, activity level and individual metabolism all play a role.

Thinking about the cost of treatment across this period? The Wegovy cost breakdown explains what private treatment covers and what market pricing currently looks like. For a broader look at weight-loss treatment options, our treatment overview puts Wegovy in context alongside the other licensed medicines.

The thing that surprises people at this stage is how much of the appetite change is invisible on the scales but visible in behaviour: fewer snacks, smaller portions, more consistent energy without the sugar highs and crashes. Those are real signals that the medicine is doing what it is licensed to do.

Maintenance and beyond: where clinical-trial results come from

The trial data that tends to appear in headlines (around 15% average weight reduction over 68 weeks, drawn from the STEP 1 trial published in the New England Journal of Medicine) reflects outcomes at the 2.4 mg maintenance dose, reached after titration and held for many months. That context matters. Expecting those results in month one sets up the wrong comparison.

Most people who experience meaningful weight loss on Wegovy are still on it at the twelve-week, six-month and twelve-month marks. The medicine works cumulatively: appetite suppression, sustained calorie reduction over time, and the body's gradual response to a sustained deficit. How quickly Wegovy starts working depends on which effect you are measuring, the appetite signal arrives early; the weight-loss outcome accumulates over months.

NICE recommends reviewing whether treatment is continuing to work after six months; if weight loss is less than 5% at the highest tolerated dose, continuing is assessed by your prescriber. That clinical checkpoint is part of why ongoing prescriber oversight matters, not just for safety but for getting the most out of treatment. Our clinical team reviews every repeat prescription before it is issued.

If you are weighing up how Wegovy compares over a full treatment course, the timeline for weight loss specifically gives a closer look at the evidence. And for a broader picture of how semaglutide works across its different uses, that pillar covers the mechanism in full.

If you would like a prescriber to assess whether Wegovy is clinically suitable for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.